poisar

Stocks · News reference

Oppenheimer Maintains Buy Rating and $75 Price Target on Definium Therapeutics

Fiscal.ai

Oppenheimer analyst Jay Olson has reaffirmed a 'Buy' rating and a $75 price target for Definium Therapeutics (DFTX).

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolThe Motley Fool Team

    Definium Therapeutics: 3 Key Takeaways for Long-Term Investors

    Definium Therapeutics announced positive Phase 3 clinical trial results for its lead psychiatric drug DT120 in generalized anxiety disorder and major depressive disorder, with plans to file for regulatory approval in the first half of 2027. The company holds $1.05 billion in cash to fund operations through 2030 and showed early efficacy signals for pipeline expansion into autism spectrum disorder with DT402.